The size of the investment was not disclosed. But it was part of Gore’s Micro-Equity Investment (MEI) program, which provides investments of up to $500,000.
W.L. Gore officials think the company’s more than 60 years in material science competence will help them solve a major technological challenge that implantable insulin delivery systems face: intraperitoneal catheter obstruction.
“Overcoming catheter obstructions plays an important role in the development of intraperitoneal insulin delivery systems,” PhysioLogic CEO Greg Peterson said in a news release.
“We look forward to the opportunity to collaborate with Gore to solve this technical challenge based on Gore’s material science capability and develop a system that offers our life-changing treatment to millions of individuals living with insulin-requiring diabetes,” Peterson said.
On top of collaborating on overcoming catheter obstruction challenges, Gore’s investment will help PhysioLogic tackle hurdles related to implantable micropumps and actuators and support the startup’s development goals for the upcoming years.